{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:37:20Z","timestamp":1778661440012,"version":"3.51.4"},"reference-count":43,"publisher":"Wiley","issue":"19","license":[{"start":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T00:00:00Z","timestamp":1649548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803070"],"award-info":[{"award-number":["81803070"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Immunotherapy\u2010antiangiogenesis combination therapy has achieved excellent survival outcomes in hepatocellular carcinoma (HCC) in clinical trials. However, the combination therapy for HCC outside clinical trials is not well studied, and predictive factors are lacking. Here, we retrospectively analyzed the efficacy and safety of immunotherapy\u2010antiangiogenesis combination therapy in unresectable HCC patients in a real\u2010world setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a four\u2010center, retrospective study of unresectable HCC patients who received the combination of programmed death 1 <jats:bold>(<\/jats:bold>PD\u20101) inhibitor and antiangiogenic agent between April 2018 and July 2021 in China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 136 patients were enrolled in the cohort. The objective response rate (ORR) and disease control rate (DCR) were 38.0% and 81.8%, respectively. The median time to progression (TTP), progression\u2010free survival (PFS), and overall survival (OS) were 7.2, 7.3, and 19.6\u2009months, respectively. The multivariate analysis indicated that ECOG performance status score (PS) 2 was a significantly independent negative factor of ORR. Moreover, ECOG PS 2, peritoneum metastasis and previous immunotherapy were found to be independent negative predictors of PFS. A shorter OS was associated with ECOG PS 2, peritoneum metastasis, the presence of previous immunotherapy, Child\u2010Pugh stage B, and high alpha\u2010fetoprotein (AFP) concentration. One hundred and twenty\u2010five patients (91.9%) reported adverse events (AEs) with any grade.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We elucidated the efficacy and safety of immunotherapy\u2010antiangiogenesis combination therapy and identified potential predictors for response and survival in a real\u2010world cohort of patients with unresectable HCC.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.4747","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T05:59:38Z","timestamp":1649656778000},"page":"3612-3622","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Efficacy and safety of <scp>PD<\/scp>\u20101 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study"],"prefix":"10.1002","volume":"11","author":[{"given":"Junlin","family":"Yao","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine Zhejiang University  Hangzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xudong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, College of Medicine Zhejiang University  Hangzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiheng","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine Zhejiang University  Hangzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital  Hangzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yibo","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery Cancer Hospital of University of Chinese Academy of Sciences Zhejiang Cancer Hospital  Hangzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine Zhejiang University  Hangzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine Zhejiang University  Hangzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine Zhejiang University  Hangzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Sir Run Run Shaw Hospital, College of Medicine Zhejiang University  Hangzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongming","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine Zhejiang University  Hangzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5915-5531","authenticated-orcid":false,"given":"Xian","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Second Affiliated Hospital, College of Medicine Zhejiang University  Hangzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7227-3671","authenticated-orcid":false,"given":"Weidong","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine Zhejiang University  Hangzhou Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,4,10]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30937-9"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00109-6"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32453-9"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1717002"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"e_1_2_11_12_1","first-page":"193","article-title":"Pembrolizumab as second\u2010line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE\u2010240: a randomized, double\u2010blind","volume":"38","author":"Finn RS","year":"2020","journal-title":"Phase III Trial JCO"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz394.029"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4564"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00808"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4152"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000505933"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00274-z"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S286169"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00395-0"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1247132"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70151-0"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00252-7"},{"key":"e_1_2_11_25_1","unstructured":"Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a non\u2010randomized open\u2010label phase 2 trial: 38."},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4078"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.03.018"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2797"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/2324709621992207"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1132"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2014.10.006"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1159\/000494843"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S187121"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.189"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.609322"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-7037"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.06.004"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0693-2"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.05.038"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107033"},{"key":"e_1_2_11_41_1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/ddg.14091","article-title":"Rechallenge with checkpoint inhibitors in metastatic melanoma. JDDG","volume":"18","author":"Reschke R","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.102816"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0180"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002191"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4747","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.4747","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T06:30:30Z","timestamp":1692685830000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.4747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,10]]},"references-count":43,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1002\/cam4.4747"],"URL":"https:\/\/doi.org\/10.1002\/cam4.4747","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,10]]},"assertion":[{"value":"2021-12-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}